IMAVAC™
Next-Generation Virus-Like Particle Technology
Vactech’s innovative IMAVAC™ technology utilizes virus-like particles (VLPs) for safe and effective vaccine development. These non-infectious particles, based on the enterovirus structure, strongly stimulate the immune system without the risk of infection.
Virus-Like Particle Platform
Advancing Vaccines and Immunotherapy
IMAVAC™ technology uses recombinant proteins to create virus-like particles that mimic viruses structurally but lack viral genetic material, ensuring safety and strong immune activation. Preclinical studies confirm that IMAVAC™ VLPs generate robust immune responses comparable to traditional vaccines. Additionally, this versatile platform shows great promise for developing new immunotherapies, expanding the potential of Vactech’s preventive medicine portfolio.